TY - JOUR
T1 - Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage ii or iii her2-negative breast cancer
AU - Mrózek, Ewa
AU - Layman, Rachel
AU - Ramaswamy, Bhuvaneswari
AU - Lustberg, Maryam
AU - Vecchione, Andrea
AU - Knopp, Michael V.
AU - Shapiro, Charles L.
N1 - Funding Information:
The work was supported in part by grants from Celgene and from Genentech . This article was presented in part at the American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL, June 4–8, 2010.
PY - 2014/8
Y1 - 2014/8
N2 - Background We hypothesized that adding bevacizumab to neoadjuvant chemotherapy (NCT) with nab-P and carboplatin would increase the rates of pCR in BC patients and that early changes in tumor vascularity imaged by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict pCR. Methods Thirty-three women with clinical stage II or III HER2-negative BC received nab-P 100 mg/m2 and carboplatin area under the curve = 2 on days 1, 8, and 15 in combination with bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days. Results Six patients (18%) achieved pCR, all pCRs occurred in triple-negative BC (TNBC) (pCR = 50% for TNBC). At the end of cycle 2, the changes in relative angiogenic volume were significantly different between responders and nonresponders (P =.001). The major toxicity of this NCT was myelosuppression. Conclusion NCT with weekly nab-P, carboplatin, and biweekly bevacizumab resulted in a pCR rate that was neither superior to the historical data with anthracycline- or taxane-containing NCT nor to carboplatin and taxane combinations in patients with HER2-negative BC. In patients with TNBC, the observed pCR rate was 50%. The early changes in the relative angiogenic volume imaged by DCE-MRI could predict pCR.
AB - Background We hypothesized that adding bevacizumab to neoadjuvant chemotherapy (NCT) with nab-P and carboplatin would increase the rates of pCR in BC patients and that early changes in tumor vascularity imaged by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) would predict pCR. Methods Thirty-three women with clinical stage II or III HER2-negative BC received nab-P 100 mg/m2 and carboplatin area under the curve = 2 on days 1, 8, and 15 in combination with bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days. Results Six patients (18%) achieved pCR, all pCRs occurred in triple-negative BC (TNBC) (pCR = 50% for TNBC). At the end of cycle 2, the changes in relative angiogenic volume were significantly different between responders and nonresponders (P =.001). The major toxicity of this NCT was myelosuppression. Conclusion NCT with weekly nab-P, carboplatin, and biweekly bevacizumab resulted in a pCR rate that was neither superior to the historical data with anthracycline- or taxane-containing NCT nor to carboplatin and taxane combinations in patients with HER2-negative BC. In patients with TNBC, the observed pCR rate was 50%. The early changes in the relative angiogenic volume imaged by DCE-MRI could predict pCR.
KW - Carboplatin
KW - Human epidermal growth factor receptor-negative breast cancer
KW - Nanoparticle albumin-bound paclitaxel
KW - Neoadjuvant chemotherapy
KW - Pathologic complete response
UR - http://www.scopus.com/inward/record.url?scp=84904647713&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84904647713&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2014.02.005
DO - 10.1016/j.clbc.2014.02.005
M3 - Article
C2 - 24703985
AN - SCOPUS:84904647713
SN - 1526-8209
VL - 14
SP - 228
EP - 234
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 4
ER -